Tropomyosin Receptor Kinase as a Target for the Treatment of Solid Tumors

NTRK fusions, although rare, have been identified as an important driver of oncogenic activity in a variety of cancer types. Advances in the understanding of TRK family biology, coupled with the growing recognition of TRK alterations as drivers of oncogenesis across tumor types, has fueled interest in the development of small molecule inhibitors of TRK.

Alexander Drilon, MD, speaks to the significance of <em>TRK </em>gene fusions and treatments for targeting these fusions in patients with cancer.